Home > > Global Advanced Therapy Medicinal Products CDMO Market Report
The Advanced Therapy Medicinal Products CDMO market was valued at $5,281.5 Million in 2022, and is projected to reach $12,216.8 Million by 2032 growing at a CAGR of 8.80% from 2023 to 2032.Advanced therapy medicinal products (ATMPs) are a type of medicinal product that uses cells or tissues as the active substance. These products have the potential to treat, prevent, or diagnose a wide range of diseases, including cancer, cardiovascular disease, and genetic disorders. The ATMP CDMO (contract development and manufacturing organization) market is expected to grow significantly in the coming years due to several factors, including: Increasing demand for personalized medicine: ATMPs are tailored to the specific needs of each patient, which makes them highly effective in treating complex diseases. Government support: Many governments are investing in the development of ATMPs, which is driving growth in the market. Technological advancements: There have been significant advances in the production and development of ATMPs, which are making them more accessible and affordable. Some of the top companies in the ATMP CDMO market include: Lonza Merck KGaA Thermo Fisher Scientific GE Healthcare Novartis These companies have made significant investments in the development of ATMPs and have established partnerships with leading research institutions to advance the field. They have also developed state-of-the-art manufacturing facilities to produce ATMPs at scale.